Skip to content

Total debt at other companies

Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
$180.9M+69.8%
Immunome logo
ImmunomeIMNM
$3.69M-22.6%
CG Oncology logo
CG OncologyCGON
$7.58M+631%
Erasca, Inc. logo
Erasca, Inc.ERAS
$45.95M-9.6%
Amgen logo
AmgenAMGN
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN

Other financials

Income statement

See full
Operating income-$71.9M-8.9%
Net income-$70.9M-6.9%
EPS (diluted)-$0.77+2.5%

Balance sheet

See full
Cash & equivalents$124.7M-28.3%
Total equity$210.5M-56.4%
Total assets$333.6M-44.7%

Cash flow

See full
Operating cash flow-$66.0M-30.1%
CapEx$135.0K-92.5%
Free cash flow-$66.1M-25.9%

Valuation

See full
Market cap$930.59M+30.2%
Enterprise value$885.15M+30.0%

Returns & leverage

See full
Return on equity-90.9%+362pp
Debt / equity0.4×+0.2×
Current ratio5.6×-5.8×

Where this comes from

Calculated from Replimune Group’s reported figures.

Plus components not separately reported this period.

The official record: Replimune Group’s 10-Q, filed February 3, 2026, on SEC EDGAR. View the filing →

Ask your AI about Replimune Group's total debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Replimune Group's total debt?
Replimune Group (REPL) reported total debt of $79.21M in Q4 2025.
How has Replimune Group's total debt changed year-over-year?
Replimune Group's total debt increased by 0.5% year-over-year, from $78.82M to $79.21M.
What is the long-term trend for Replimune Group's total debt?
Over 4 years (2021 to 2025), Replimune Group's total debt has grown at a 21.9% compound annual growth rate (CAGR), from $35.77M to $78.96M.
What does total debt mean?
Total debt represents the aggregate sum of all interest-bearing financial obligations, including short-term borrowings, the current portion of long-term debt, and long-term debt instruments. It also encompasses capitalized lease liabilities and other debt-like financing arrangements that require fixed repayment schedules. This metric serves as a comprehensive indicator of a company's total financial leverage and its reliance on external capital providers.